Today, we’re diving into a condition that’s as fascinating as it is complex:
Achalasia—where the esophagus stops playing nice, and swallowing becomes a daily challenge.
We’re breaking down the
latest evidence, comparing
POEM, pneumatic dilation, and Heller myotomy, and digging into what actually matters when deciding how to treat each achalasia subtype.
Join show hosts Drs. Jake Greenberg, Dana Portenier, Zach Weitzner, and Joey Lew as they discuss the past, present, and future of Achalasia management. Whether you're a medical student or a seasoned attending, this episode will arm you with the tools to think critically about diagnosis, tailor your treatment strategy, and stay ahead of the curve on the future of achalasia care.
Hosts:
· Jacob Greenberg, MD, EdM, MIS Division Chief and Vice Chair for Education, Duke University
· Dana Portenier, MD, MIS Fellowship Director, Duke University
· Zachary Weitzner, MD, Minimally Invasive and Bariatric Surgery Fellow, Duke University, @ZachWeitznerMD
· Joey Lew, MD, MFA, Surgical resident PGY-3, Duke University, @lew__actually
Learning Goals:
By the end of this episode, listeners will be able to:
·
Describe the pathophysiology and key diagnostic criteria for achalasia, including the role of manometry, EGD, and esophagram.
·
Differentiate between the three subtypes of achalasia based on the Chicago Classification and understand the clinical significance of each.
·
Compare treatment options for achalasia—pneumatic dilation, Lap Heller myotomy, and POEM—including indications, efficacy, and long-term outcomes.
·
Interpret landmark studies (e.g., European Achalasia Trial, JAMA POEM trial) and their impact on treatment decision-making.
·
Recognize patient-specific factors (age, comorbidities, achalasia subtype) that influence the choice of therapy.
·
Discuss evolving technologies and future directions in achalasia management, including endoluminal robotics, ARMS, and combined anti-reflux strategies.
·
Outline a basic treatment algorithm for newly diagnosed achalasia, incorporating diagnostic steps and tailored interventions.
·
Appreciate the multidisciplinary approach to achalasia care, including the roles of MIS surgeons, gastroenterologists, and emerging procedural skillsets.
References:
·
Boeckxstaens G, Elsen S, Belmans A, Annese V, Bredenoord AJ, Busch OR, Costantini M, Fumagalli U, Smout AJPM, Tack J, Vanuytsel T, Zaninotto G, Salvador R; European Achalasia Trial Investigators. 10‑year follow-up results of the European Achalasia Trial: a multicentre randomised controlled trial comparing pneumatic dilation with laparoscopic Heller myotomy.
Gut. 2024 Mar;73(4):582‑589. doi: 10.1136/gutjnl‑2023‑331374. PMID: 38050085
https://pubmed.ncbi.nlm.nih.gov/38050085/
·
He J, Yin Y, Tang W, Jiang J, Gu L, Yi J, Yan L, Chen S, Wu Y, Liu X.
Objective Outcomes of an Extended Anti‑reflux Mucosectomy in the Treatment of PPI‑Dependent Gastroesophageal Reflux Disease (with Video).
J Gastrointest Surg. 2022 Aug;26(8):1566–1574. doi:10.1007/s11605‑022‑05396‑9. PMID: 35776296
https://pubmed.ncbi.nlm.nih.gov/35776296/
· Modayil RJ, Zhang X, Rothberg B, et al. Peroral endoscopic myotomy: 10-year outcomes from a large, single-center U.S. series with high follow-up completion and comprehensive analysis of long-term efficacy, safety, objective GERD, and endoscopic functional luminal assessment.
Gastrointest Endosc. 202
Published on 4 months, 4 weeks ago